In fact, PF02341066, known as Crizotinib, has been approved by the U.S. Food and Drug Administration for the treatment of ALK-rearranged NSCLC in August 2011 [27], which supports the prediction from our system approach. The gene discussed is ALK; the disease is non-small cell lung carcinoma.